Cassava Defends Alzheimer’s Asset in Response to Data Manipulation Allegations

Cassava Sciences on Friday reiterated its confidence in the underlying science of its lead late-stage Alzheimer’s asset simufilam, which the biopharma company will continue to advance through a Phase III clinical development program.